Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 15/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10264961 | 0.87 | RAF1 (0.40) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL29273316 | 0.85 | NOTUM (0.47) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL161668 | 0.81 | RAF1 (0.56) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1912332 | 0.80 | NPSR1 (0.41) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL9965178 | 0.79 | RAF1 (0.51) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL173108 | 0.79 | RAF1 (0.56) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL10264809 | 0.79 | L3MBTL1 (0.53) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL161941 | 0.79 | L3MBTL1 (0.60) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL319034 | 0.78 | GSK3B (0.53) | L3MBTL1MAPT | |
| SCHEMBL14467713 | 0.78 | RAF1 (0.60) | RAF1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012010663-A9 | 2,3,5-TRISUBSTITUTED THIOPHENE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2013-01-24 | — | — | WO | disclosed |
| WO-2012024363-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012010663-A1 | 2,3,5-TRISUBSTITUTED THIOPHENE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012006055-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | WO | disclosed |
| US-7741479-B2 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| WO-2010019930-A1 | UREA DERIVATIVES AS INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | MAP4K2, MAP3K1, MAP3K20 | RAF1 74/4885MAPK14 33/4885MAPK13 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.